Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Okairos AG
Trio Plans Anti-COVID-19 Vaccine Derived From Simian Adenoviruses
Three European biotechs have joined forces to develop and manufacture a simian adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Boehringer's Expanded Venture Fund: Innovation First, Returns Second
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
- Gene Therapy, Cell Therapy
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.